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Abstract 
A cDNA clone encoding a human ribosomal protein L39 (hRPL39) was isolated through a random cDNA sequencing approach to a 
cDNA library constructed from a human colon carcinoma cell line of COLO 205. Although levels of hRPL39 mRNA were different in 
several cell lines including carcinoma cell lines from different issues, they were shown not to be cell cycle-dependent i  a human 
fibroblast cell line of TIG-1. 
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Carcinogenesis  thought o occur as a consequence of 
multistep alterations in genes [1,2]. In addition to muta- 
tions or deletions of certain genes, secondary molecular 
changes in carcinomas contribute to their malignant pheno- 
types to a certain extent. These secondary changes provide 
us with important information concerning the molecular 
basis of carcinoma nd may lead us to find markers for the 
disease or a new therapeutic target. A random cDNA 
sequencing approach has recently become an effective 
method to obtain a group of genes expressed in specific 
states of cells or tissues by generating expressed sequence 
tags [3-6]. We applied a random cDNA sequencing ap- 
proach to a human colon carcinoma cell line of COLO 205 
[7], and isolated several cDNAs encoding ribosomal pro- 
teins. Among them, one was found to encode a human 
homologue of rNRPL39. 
Cell preparation, cDNA construction, sequencing and 
analysis of cDNAs, RNA extraction, and Northern blot 
analysis were performed as previously described [7]. TIG- l  
cells (a normal human fibroblast cell line) cultured to 
subconfluence were synchronized in the quiescent G o state 
by culturing them in DMEM supplemented with 0.5% 
Abbreviations: DMEM, Dulbecco's modified Eagle's medium; FCS, 
fetal calf serum; hRP, human ribosomal protein; rNRP, rattus norvegicus 
ribosomal protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. 
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FCS. The medium was changed on days 2 and 4. On day 
6, the medium was changed to DMEM with 10% FCS to 
stimulate their growth [8]. Total RNA of TIG-1 was ex- 
tracted by the acid guanidium thiocyanate-phenol-chloro- 
form method [9] at 0, 6, 12, 18, and 24 h after growth 
stimulation and used for Northern blot analysis. Quantifi- 
cation of Northern blot analysis was performed by Fujix 
BAS 2000 phosphorimaging plates and a phosphorimager 
(Fuji, Tokyo, Japan) with the quantities tandardized for 
the GAPDH message as a control. 
We randomly picked up 1056 cDNA clones from the 
cDNA library constructed from COLO 205 and sequenced 
them by a single path sequencing [7]. The obtained se- 
quences were compared with each other at first to assess 
the frequency of their appearance in our library, and then 
with the DNA data base in GenBank using a FASTA 
program [10,11]. Out of 526 independent cDNA species, 
we obtained 45 species encoding partial sequences of 
ribosomal proteins with frequencies of appearance in the 
library ranging from one to nine times. Of these 45 
independent cDNA species, 22 were found only once, and 
the clone we report here was one of them. 
While analyzing the sequences of the cDNA clones, we 
came across a cDNA which was not identified in humans 
before and is highly homologous to rNRPL39. Only the 
partial sequences were found in the DNA databases with 
the accession numbers L05096 and D28397 [12,13]. The 
nucleotide sequence determined by sequencing both strands 
of the cDNA three times and the deduced amino acid 
sequence are shown in Fig. 1. The cDNA included 37 
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CAGCCATCGTGGTGTGTTCTTGACTCCGCTGCTCGCCATGTCTTCTCACAAGACTTTCAG 
M S S H K T F R 
70 80 90 I00 I I0 120 
GATTAAGCGA TTCC TGGC CAAGAAACAAAAGCAAAATCGTC C ATTC C C CAGTGGATTC G 
I K R F L A K K Q K Q N R P I P Q W I R 
130 140 150 160 170 180 
GATGAAAACTGGAAATAAAATCAGGTACAAC TCCAAAAG GAGACATTGGAGAAGAACCAA 
M K T G N K I R Y N S K R R H W R R T K 
190 200 210 220 230 240 
GC TGGGTC TATAAGGAATTGCACATGAGAT~C ACATATTTAT GC TGTCTGAAGGTCA 
L G L * 
250 260 270 280 290 300 
C GAT CATGTTACCATATCAAGCTGAAAATGTCAC CAC TATC TGGAGATTTC GACGTGTTT 
310 320 330 340 350 360 
TCCT C TCTGAATCTGTTATGAAC ACGTTGGTTGGC TGGATTC AGTAATAAATATGTAAGG 
370 
CC~C'I"I"I"I"i' 
Fig. l. The full length nucleotide sequence of hRPL39 and its deduced 
amino acid sequence. The numbered positions of nucleotides are indi- 
cated above the sequence and the polyadenylation signal is underlined. 
5'-non-coding nucleotides, an open reading frame of 153 
nucleotides, and 181 nucleotides in the 3'-untranslated 
region, followed by a poly(A) tail. The polyadenylation 
signal, AATAAA,  was located at nucleotides 346 to 351. 
The open reading frame specified a protein of 51 amino 
acids with the theoretical molecular weight of 7307. The 
nucleotide sequence of the eDNA shared 90.8% similarity 
(14 different nucleotides out of 181 nucleotides) within the 
coding region (Fig. 2A), and its deduced amino acid 
sequence shared 100% similarity with that of rNRPL39 
(Fig. 2B). These results identified this eDNA as that for 
hRPL39. 
We examined the levels of hRPL39 mRNA among 
different organs by Northern blot analysis (Fig. 3A). The 
signals were observed by cross-hybridization f an hRPL39 
eDNA probe with mRNAs in organs of mice due to 
difficulty to obtain human tissues. RPL39 was ubiquitously 
expressed in all organs we examined. Lung and spleen 
showed about two-fold increased amounts of RPL39 
mRNA when compared with those in other organs. 
Because ribosomal proteins were reported to be overex- 
pressed in carcinoma ceils and tissues [14-21], the levels 
of hRPL39 mRNA were examined in cultured human cell 
lines. Fig. 3B shows a representative Northern blot analy- 
(A) 
ATGTCTTC TCACAAGACTTTCAGGATTAAGCGATTCCTGGC C AAGAA CAAAAC-CAAAAT 
***********************  ** **************  ******************  
ATGTC TTC TCACAAGACTTTCAGAATC AAGCGATTC CTGGC AAAGAAACAAAAGCAAAAT 
C GTC CCATTC C CCAGTGGATTCGGATGAAAAC TGGAAATAAAATCAGGTACAACTCCAAA 
*****  ***** ** ********************  ** *****************  ** 
C GTC CTATTCC TCAATGGATTC GGATGAAAAC TGGTAACAAAATCAGGTACAAC~C TAAG 
AGGAGACATTGGAGAAGAACCAAGC TGGGTC TA 
** ***** ***** ***** ************  
AGAAGACAC TG GAGGAGAAC GAAGCTGGGTC TA 
(B) 
MS S H KTFRI  KRFLAKKQKQNRP I PQWI  RMKTGNK I RYNS KRRHWRRTKLGL 
***************************************************  
MS SHKTFRIKRFLAKKQKQNRP I PQWI RMKTGNKIRYNSKRPJ{WRRTKLGL 
Fig. 2. Comparison of the nucleotides and deduced amino acids of 
hRPL39 with those of rNRPL39 within the open reading frame. (A) 
hRPL39 showed 90.8% similarity at the nucleotide sequence and (B) 
100% similarity at the amino acid sequence with the rat counterpart. 
(upper panel, hRPL39; lower panel, rNRPL39). 
sis of hRPL39 in COLO 205, CW2 (a human colon 
carcinoma cell line), hNCI-H520 (a human lung squamous 
carcinoma cell line), and TIG-1. In comparison to hRPL39 
mRNA in TIG-1, it was expressed almost at the same level 
in CW2, about wo-fold higher in COLO 205 and three-fold 
higher in hNCI-H520, based on the quantitation using a 
phosphorimager (Fuji) (data not shown). These different 
expression levels may reflect the origin of tissues from 
which they were derived, because hNCI-H520 and lung 
showed a relatively high hRPL39 mRNA expression level. 
However, the mRNA level of hRPL39 was two-fold higher 
in COLO 205 than that in CW2, despite that they were 
derived from the same colonic origin. These altered mRNA 
levels may reflect different malignant phenotypes of these 
cells, because the mRNA level of a certain ribosomal 
protein was reported to correlate with colorectal carcinoma 
progression and its biological aggressiveness [14]. 
The mRNA of another human ribosomal protein S13 
which was also overexpressed in carcinoma cells, was 
reported to correlate with the in vitro proliferative rate 
[15]. In addition, expression of several growth-associated 
(A) (B) (C) 
. . . . . . . . .  
-28S 
-IlK~ -18S -18S 
Fig. 3. Northern blot analysis of hRPL39. (A) RNA samples of brain, heart, lung, liver, spleen, kidney, and intestine which were abbreviated as Br, He, Lu, 
Li, Sp, Ki, and In, respectively, were extracted from C57BL/6 mice. Twelve micrograms each of total RNA were cross-hybridized with an hRPL39 cDNA 
probe. (13) Twelve micrograms of total RNA samples from COLO205, CW-2, hNCI-H520, and TIG-I, which were abbreviated asC, W, N, and T, 
respectively, were hybridized with an hRPL39 eDNA probe. (C) Total RNAs of TIG-1 at 0, 6, 12, 18, and 24 h after growth stimulation were hybridized 
with an hRPL39 eDNA probe. All blots were rehybridized with a murine GAPDH eDNA probe as a control (lower panel), The positions of 18S and 28S 
rRNA are indicated. 
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genes such as c-myc [22], c-myb [23], cyclin, and thymi- 
dine kinase [24], was reported to be cell cycle-dependent. 
However, little is known about the relationship between 
the cell cycle and the expression level of ribosomal pro- 
teins. Thus, we examined the expression of hRPL39 for its 
cell cycle-dependency in TIG-1. TIG-1 was used because 
hRPL39 was expressed at a fairly high level, and because 
they had been well analyzed for their cell cycles. TIG-I 
cells were first synchronized to G O phase with serum 
starvation by 0.5% FCS, and their growth was stimulated 
by increasing the FCS concentration up to 10% as de- 
scribed [8]. As shown in Fig. 3C, the hRPL39 mRNA 
levels standardized for the GAPDH message were not 
significantly changed in TIG-I (about 1.3-fold at most) 
during 24 h after the cell growth stimulation, suggesting 
that hRPL39 mRNA is stably expressed throughout i s cell 
cycle phases. These results are consistent with the notion 
that the altered protein synthetic capacity in different 
growth states is based on changes in translation of riboso- 
mal protein mRNA, rather than changes in mRNA abun- 
dance or stability, except for the condition where de- 
creased mRNA levels were observed associated with dif- 
ferentiation [25]. 
It is likely that a subset of ribosomal proteins is overex- 
pressed to produce other essential proteins to keep up with 
the high level proliferation and/or maintaining malignant 
phenotypes in certain carcinomas, because ribosomal pro- 
teins play an important role in protein synthesis via forma- 
tion of ribosomal subunits [26]. Careful future studies on 
the relationship between malignant phenotypes of carcino- 
mas and expression patterns of ribosomal proteins hould 
help us to understand the significance of their overexpres- 
sion in carcinomas, which may afford us therapeutic tar- 
gets of carcinomas. 
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